A new policy report urges sweeping FDA reforms, arguing that shortening the time required to bring drugs, biologics and medical devices to market could generate trillions of dollars in benefits for patients, innovators and the broader economy.
Law firms Hogan Lovells and Foley and Lardner advise pharmaceutical and medical device companies to maintain full inspection readiness while FDA undergoes a shift to one-day, streamlined inspections at low-risk facilities.
A new policy report urges sweeping FDA reforms, arguing that shortening the time required to bring drugs, biologics and medical devices to market could generate trillions of dollars in benefits for patients, innovators and the broader economy.
Law firms Hogan Lovells and Foley and Lardner advise pharmaceutical and medical device companies to maintain full inspection readiness while FDA undergoes a shift to one-day, streamlined inspections at low-risk facilities.
Former FDA commissioner Andrew C. von Eschenbach and former HHS secretary Tommy G. Thompson urge policymakers to prioritize leadership and institutional stewardship over professional credentials as the search continues for the next FDA commissioner.
FDA appoints Lisa Romano as principal deputy associate commissioner for inspections and investigations, elevating a 24-year agency veteran to one of the top leadership positions within the agency's inspection and enforcement organization.
